Relationship Between BRAF V600E or TERT Promoter Mutations and Loss of RAI Avidity in Recurrent PTC
| Loss of RAI | Odds ratio | |||
| Tumor type and mutation status | n | P | Unadjusted | Adjusted* |
| All PTC | ||||
| BRAF V600E | ||||
| Negative | 21/62 (33.9) | 1.00 | 1.00 | |
| Positive | 82/102 (80.4) | <0.001 | 7.88 (3.69–17.51) | 7.11 (3.24–16.27) |
| TERT mutation | ||||
| Negative | 61/117 (52.1) | 1.00 | 1.00 | |
| Positive | 42/47 (89.4) | <0.001 | 7.63 (2.75–26.46) | 6.89 (2.28–25.66) |
| CPTC | ||||
| BRAF V600E | ||||
| Negative | 10/39 (25.6) | 1.00 | 1.00 | |
| Positive | 71/87 (81.6) | <0.001 | 12.52 (4.82–35.27) | 10.78 (4.03–31.38) |
| TERT mutation | ||||
| Negative | 47/91 (51.6) | 1.00 | 1.00 | |
| Positive | 34/35 (97.1) | <0.001 | 31.23 (4.81–1,322.43) | 31.37 (4.39–1,402.18) |
↵* Adjusted for patient age and sex.
CPTC = conventional PTC.
TERT promoter mutations here included, collectively, TERT C228T and TERT C250T. Data in parentheses are percentages or 95% CIs.